A total of 112 patients with recurrent lower urinary tract infection (UTI) completed the 6-month period of the trial. Patients were treated for 3 months, under double-blind conditions, with one capsule daily of either Uro-Vaxom (UV) or placebo, together with an antibiotic or chemotherapeutic agent when necessary, and observed for a further 3 months. During the 6 months of the trial a significant decrease in the number of recurrences (p < 0.0005) was noted in the UV group as compared to the placebo group. A total of 67.2% of the patients had no recurrences (p < 0.0005). The incidence of bacteriuria (germs > or = 10(5)/ml), dysuria and leukocyturia was significantly reduced. UV was well tolerated, no side effects were recorded during the trial. The drug is a useful adjuvant for the management of UTIs and for the prevention of recurrences.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000475363 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of Machine Learning to Assess the Management of Uncomplicated Urinary Tract Infection.
JAMA Netw Open
January 2025
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Healthcare Institute, Boston, Massachusetts.
Importance: Uncomplicated urinary tract infection (UTI) is a common indication for outpatient antimicrobial therapy. National guidelines for the management of uncomplicated UTI were published in 2011, but the extent to which they align with current practices, patient diversity, and pathogen biology, all of which have evolved greatly in the time since their publication, is not fully known.
Objective: To reevaluate the effectiveness and adverse event profile for first-line antibiotics, fluoroquinolones, and oral β-lactams for treating uncomplicated UTI in contemporary clinical practice.
Long-term effects of superselective renal artery embolization on renal function after percutaneous nephrolithotomy.
World J Urol
January 2025
Department of Urology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Objectives: To investigate the long-term impact of superselective renal artery embolization (SRAE) on renal function in cases of severe post-percutaneous nephrolithotomy (PCNL) haemorrhage, and to identify the factors associated with the long-term outcome of renal function.
Methods: Patients treated with SRAE for post-PCNL hemorrhage between September 2016 and September 2021 were included. Patients' demographic and clinical data were recorded.
Efficacy of 100-U Onabotulinumtoxin A Treatment in Female Idiopathic Overactive Bladder-A Prospective Follow-Up Study.
Int Urogynecol J
January 2025
Department of Obstetrics and Gynaecology, Medical Research Center Oulu, Research Unit of Clinical Medicine, University of Oulu and Oulu University Hospital, Kajaanintie 50, BOX 5000, 90014, Oulu, Finland.
Introduction And Hypothesis: Overactive bladder (OAB) affects 11-17% of the female population. First-line treatment with lifestyle modifications and second-line therapy with medications are often limited by inadequate efficacy or pharmacological side effects. This study was aimed at assessing the effect of 100 U onabotulinumtoxin A treatment on idiopathic OAB (iOAB) as a second-line treatment.
View Article and Find Full Text PDFEffects of ileal conduit length on long-term kidney function decline after total pelvic exenteration for colorectal cancer.
Colorectal Dis
February 2025
Department of Gastrointestinal Surgery, Institute of Science Tokyo, Tokyo, Japan.
Aim: Understanding of kidney function decline (KFD) after pelvic exenteration (PE) for colorectal cancer remains limited, and the effects of a long ileal conduit (IC) on kidney disorders are unclear. The aim of this study was to investigate long-term kidney function following PE in colorectal cancer and to evaluate the effects of IC length on KFD.
Method: This was a retrospective, single-centre cohort study.
Pemafibrate ameliorates renal injury through induction of FGF21 and ketone body production in male mice.
Physiol Rep
February 2025
Department of Molecular Medicine and Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Chronic kidney disease is a life-threatening disease worldwide. PPARα is a crucial transcriptional regulator of lipid metabolism and inflammation. Here, we examine whether a novel selective PPARα modulator, pemafibrate modulates renal injury in a model of unilateral ureteral obstruction (UUO).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!